Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2334 - Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis


09 Oct 2016


Poster display


Andrea Necchi


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


A. Necchi1, G.R. Pond2, D. Raggi3, S. Ottenhof4, S. Horenblas4, V. Khoo5, O. Hakenberg6, A. Heidenreich7, B.J. Eigl8, L. Nappi9, K. Matsumoto10, U. Vaishampayan11, M. Woods12, P. Giannatempo13, D. Geynisman14, M. Preto15, E. Xylinas16, M.I. Milowsky17, G. Di Lorenzo18, G. Sonpavde19

Author affiliations

  • 1 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Oncology, McMaster University, Hamilton/CA
  • 3 Medicine, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 4 Urology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam/NL
  • 5 Medicine, Royal Marsden Hospital NHS Foundation Trust, London/GB
  • 6 Urology, Universitätsklinikum Rostock, Rostock/DE
  • 7 Urology, Uniklinik Köln, Universitätsfrauenklinik Köln, Köln/DE
  • 8 Oncology, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 9 Urological Sciences, Vancouver Prostate Centre-Vancouver General Hospital, V6H 3Z6 - Vancouver/CA
  • 10 Urology, Kitasato University East Hospital, Sagamihara/JP
  • 11 Medical Oncology, Karmanos Cancer Institute, Detroit/US
  • 12 Urology, Lineberger Comprehensive Cancer Center University of North Carolina, Chapel Hill/US
  • 13 Dept. Genitourinary, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 14 Medical Oncology, Fox Chase Cancer Center, Philadelphia/US
  • 15 Urology, Università degli Studi di Torino, Torino/IT
  • 16 Urology, Hôpital Cochin, Paris/FR
  • 17 Medical Oncology, Lineberger Comprehensive Cancer Center University of North Carolina, Chapel Hill/US
  • 18 Medical Oncology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, Napoli/IT
  • 19 Medical Oncology, University of Alabama at Birmingham Hospital, 35294-3280 - Birmingham/US


Abstract 2334


Patients (pts) with LA-PSCC have a poor prognosis, primarily related to extent of nodal disease, and surgery alone is suboptimal in most cases. Information on patient outcomes with PO-CT still relies on small numbers.


A retrospective, multicenter, individual patient-level analysis was performed. A total of 12 centers contributed data for pts who received neoadjuvant (NA) or adjuvant (A) CT in addition to surgery from 1991 to 2016. Cox regression models investigated potential prognostic factors (PF) for relapse-free (RFS) and overall survival (OS). Multivariable (MVA) models were constructed to evaluate treatment effects. Treatment center was used as a stratification factor.


201 pts were analyzed. At clinical staging, 20 (10%) had cT3-4N0 disease, 68 (33.8%) cN3, 42 (20.9%) pelvic nodes and 76 (37.8%) a bilateral involvement. 70 (34.8%) had recurrence after prior lymphadenectomy (LAD). 94 pts received NA-CT, 78 A-CT, and 21 NA and A-CT (8 unknown). Taxanes were more frequently used in NA (75%) than in A setting, with taxane-CDDP-5FU being the most frequent NA CT regimen (n = 65). 43 pts (21.4%) received concomitant radiotherapy (RT). The 2-year OS (95%CI) for all pts was 43.7% (35.8-51.3), however among pelvic cN+ and bilateral cN+ subgroups it was 37.4% (20.5-54.4) and 38.1% (25.9-50.1). On MVA for OS (n = 166), bilateral disease (HR: 1.93, 95%CI: 1.04-3.56, p = 0.037) was a negative PF, while pelvic cN+ trended toward significance (HR: 2.26, 95%CI: 0.96-5.36, p = 0.063). 50 pts (53.2%) had an objective response to NA-CT, and 13 (13.8%) achieved a pathologic CR. Timing of CT (NA vs A vs NA > A) was significantly associated with RFS (NA: HR: 4.55, 95%CI: 1.35-15.36, p = 0.012) in univariable analysis, but not with OS (p = 0.45). No significant difference was observed in any outcome related to CT type or CT ± RT.


The survival benefit from PO-CT, either pre- or post-LAD, remained uncertain for PSCC pts at highest risk (pelvic cN+ or bilateral lymph-node disease). These results may be useful to inform pts and provide a benchmark for prospective studies. Further research should identify more active drugs in PSCC and evaluate the role of RT.

Clinical trial identification


Legal entity responsible for the study

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy


Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings